SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-21-278394
Filing Date
2021-09-21
Accepted
2021-09-21 17:04:53
Documents
1
Group Members
DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLCXIANGMIN CUI

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d201046dsc13da.htm SC 13D/A 120910
  Complete submission text file 0001193125-21-278394.txt   122712
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Subject) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88896 | Film No.: 211267101
SIC: 2834 Pharmaceutical Preparations

Mailing Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital China Life Sciences USD Fund III, L.P. (Filed by) CIK: 0001736814 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A